Global markets
Neurocrine acquires Soleno for $2.9 billion in cash deal
April 6: Neurocrine Biosciences agreed to acquire Soleno Therapeutics at $53/share in an all-cash transaction valued at $2.9 billion.
Primary sources · 1
April 6: Neurocrine Biosciences agreed to acquire Soleno Therapeutics at $53/share in an all-cash transaction valued at $2.9 billion.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.